Mechanistic role of a disease-associated genetic variant within the ADAM33 asthma susceptibility gene by Del Mastro, Richard G et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Mechanistic role of a disease-associated genetic variant within the 
ADAM33 asthma susceptibility gene
Richard G Del Mastro*1, Laura Turenne2, Heidi Giese1, Tim P Keith3, 
Paul Van Eerdewegh3, Klaus JW May4 and Randall D Little3
Address: 1Molecular Therapeutics Division, AmberGen Incorporated, Waltham, Massachusetts 02453, USA, 2Cambridge, MA 02139, USA, 
3Genomatix Software GmbH, D-80335 Munich, Germany and 4Genizon BioSciences, Quebec, H4T 2C7, Canada
Email: Richard G Del Mastro* - rdm@ambergen.com; Laura Turenne - laura_freeman2@yahoo.com; Heidi Giese - heidi@ambergen.com; 
Tim P Keith - tim.kieth@genizon.com; Paul Van Eerdewegh - paul.vaneerdewegh@genizon.com; Klaus JW May - may@genomatix.de; 
Randall D Little - randall.little@genizon.com
* Corresponding author    
Abstract
Background:  ADAM33 has been identified as an asthma-associated gene in an out-bred
population. Genetic studies suggested that the functional role of this metalloprotease was in airway
remodeling. However, the mechanistic roles of the disease-associated SNPs have yet to be
elucidated especially in the context of the pathophysiology of asthma. One disease-associated SNP,
BC+1, which resides in intron BC toward the 5' end of ADAM33, is highly associated with the
disease.
Methods:  The region surrounding this genetic variant was cloned into a model system to
determine if there is a regulatory element within this intron that influences transcription.
Results: The BC+1 protective allele did not impose any affect on the transcription of the reporter
gene. However, the at-risk allele enforced such a repressive affect on the promoter that no protein
product from the reporter gene was detected. These results indicated that there exists within
intron BC a regulatory element that acts as a repressor for gene expression. Moreover, since SNP
BC+1 is a common genetic variant, this region may interact with other undefined regulatory
elements within ADAM33 to provide a rheostat effect, which modulates pre-mRNA processing.
Thus, SNP BC+1 may have an important role in the modulation of ADAM33 gene expression.
Conclusion: These data provide for the first time a functional role for a disease-associated SNP
in ADAM33 and begin to shed light on the deregulation of this gene in the pathophysiology of
asthma.
Background
Over the past two decades, the paradigm for the identifi-
cation of genes that cause monogenic diseases has proven
to be extremely successful. Analytical and experimental
tools that employ family-based linkage methods to scan
the genome have identified major genes with causative
mutations. These monogenic diseases are rare in nature
but the disruption that is introduced into a single gene
produces a large phenotypic effect. The application of the
same tools to common disorders has proven to be far less
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lucrative. This is due to the complexity of polygenic disor-
ders where the contributing effect of a single gene is
reduced [1]. However, improved analytical methodolo-
gies that augment the power of association studies have
revealed the location of elusive genes that underlie com-
plex disease phenotypes [2-4]. Linkage disequilibrium
mapping in combination with the discovery of millions of
single nucleotide polymorphisms (SNPs) have led to the
development of high resolution haplotype maps that can
be utilized to discover disease-associated loci [5-7]. This
has led to a resurgence of the positional cloning paradigm
and the identification of disease-susceptibility genes.
Using these approaches, the first asthma susceptibility
gene, ADAM33 (A Disintegrin And Metalloprotease 33),
was discovered in an outbred population. Linkage analy-
sis was conducted on 460 Caucasian affected sib-pair fam-
ilies from UK and US populations. Significant linkage to
asthma and bronchial hyperresponsiveness was identified
in close proximity to the tip of the p-arm of chromosome
20. A subset of 130 unrelated asthma cases, which showed
significant evidence of linkage to this region, and 217
unrelated controls were utilized in a case-control study on
135 SNPs that fell within the 90% confidence interval.
Multiple SNPs and SNP pairs that were typed in ADAM33
were found to be associated with asthma and bronchial
hyperresponsiveness [8]. Replication studies in diverse
ethnic asthma populations reproduced the original work
identifying multiple SNPs within the gene having associa-
tion with asthma and its sub-phenotypes [9-20]. While
these genetic studies have identified ADAM33 alleles that
are associated with an asthma phenotype, the mechanistic
role of the SNPs in the development of the disease symp-
toms has yet to be determined.
The locations of the ADAM33 disease-associated SNPs are
within the coding and 3'untranslated regions as well as
deep within introns [8]. While it is not always immedi-
ately evident as to the affect of a single nucleotide change
on the function of the protein, several SNPs within the
exons were found to introduce amino acid changes and
provided some insight as to how they could disrupt the
protein molecule [21]. Other exonic SNPs were found to
be synonymous and cast little information as to their dis-
ruptive traits. The same was observed for the deep intronic
and 3'UTR variants [8]. However, studies in recent years
on the mechanistic role of genomic variants, whether they
reside within introns or exons of a gene, have demon-
strated that they can disrupt pre-mRNA splicing. The con-
sequence of such a disruption is to induce exon skipping,
enhance the use of cryptic splice sites and alter the ratio of
alternatively spliced isoforms. Such perturbations have
been shown to be the cause of various human disease phe-
notypes [22-27]. Furthermore, studies have shown that
the promoter of a gene plays a role in exon selection as
well as dictating the levels of transcription, indicating that
pre-mRNA splicing is a complex set of events that can be
perturbed by single or multiple genetic variants [28].
Determining the mechanistic role of disease-associated
SNPs has proven to be challenging [29]. In ADAM33 there
are several SNPs that are associated with the asthma phe-
notype. One SNP, BC+1, has been shown to have one of
the highest associations with asthma (p = 0.0027) [30].
This genetic variant is located toward the 5' end of the
ADAM33 gene deep within intron BC. In addition, com-
parative sequence analysis of this region with the mouse
ADAM33 intron BC and the surrounding area has identi-
fied regions that are highly conserved between the two
species [31]. This would suggest that there are conserved
non-coding sequences (CNS) in this region of the gene
that may contain regulatory elements. Furthermore, SNP
BC+1 appears to be located within a CNS as well as in
close proximity to other conserved regions (Fig. 1). We
present data which shows for the first time that the genetic
variant, SNP BC+1, has the functional capacity to disrupt
transcription and lies within a critical region of ADAM33.
Understanding the mechanistic role of this disease-associ-
ated SNP would begin to provide some insight into the
effect of other genetic variants in this gene and how they
may contribute to the asthma phenotype.
Methods
Cell culture
SV40 transformed lung fibroblasts (WI-38) (American
Type Cultue Colection, Manassas, VA) were maintained in
Eagle MEM (Invitrogen Corporation, Carlsbad, CA), 10%
fetal calf serum (Invitrogen Corporation, Carlsbad, CA)
and supplemented with 5 mM L-glutamine (Invitrogen
Corporation, Carlsbad, CA) and 1.0 mM sodium pyruvate
(Invitrogen Corporation, Carlsbad, CA). The cells were
grown in T75 flasks until confluent. After this 5 × 106 cells
were aliquoted into 6-well culture plates for transfection,
in triplicate, of the constructs and controls in triplicate.
Cloning intron BC
Six fragments of varying sizes from intron BC (4 spanned
the SNP and 2 flanked it, which served as internal con-
trols) (Fig. 1) were PCR amplified from BAC RP11-
1098L22 (GenBank Accession no. AF466288) (Invitrogen
Corporation, Carlsbad, CA). All primers were designed
with 6T's (to allow efficient digestion) followed by a NheI
(forward) and a BglII (reverse) restriction site at the 5' end
(underlined). This was then proceeded by ADAM33 18 to
21 nucleotides of the ADAM33 intron BC sequence.
Construct #1/#4/#5 Fwd: TTTTTTGCTAGCGTTGACCA-
GAACATGTGACCBMC Medical Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2350/8/46
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Construct #2/#6 Fwd: TTTTTTGCTAGCGCCATGAAG-
GCTGAGAGGC
Construct #3 Fwd: TTTTTTGCTAGCGGCAAGGAC-
CATCTGCTCC
Construct #1/#2/#3 Rev: TTTTTTAGATCTGCTCCGACAC-
CTGCTTCAC
Construct #4 #6 Rev: TTTTTTAGATCTGGAGCAGAT-
GGTCCTTGCC
Construct #5 Rev TTTTTTAGATCTGCCTCTCAGCCT-
TCATGGC
The fragments were amplified by PCR using the Phusion
High Fidelity DNA polymerase using conditions recom-
mended by the manufacturer (New England Biolabs, Bev-
erly, MA). PCR fragments were verified by gel
electrophoresis, digested with NheI and BglII, gel purified
with Qiaex II (Qiagen, Valencia, CA) and cloned into the
multiple cloning site of the pSEAP2-control vector from
the BD Great EscAPe SEAP Reporter System 3 kit (BD Bio-
sciences, San Jose, CA). The vector contained a reporter
gene, alkaline phosphatase, whose protein product is
secreted into the conditioned medium and used to quan-
titate the functional effect of the alleles. Sequence analysis
of the six clones was performed (Agencourt Biosciences,
Beverly, MA) to ensure that no alterations had occurred
during the PCR and cloning processes. The 4 clones that
spanned the SNP BC+1 possessed the protective allele (A).
Site directed mutagenesis
Quick Change Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA) was utilized to change the nucleotide at SNP
BC+1 from an A (protective) to a G (at-risk) in Constructs
#1, #2, #4 and #6 following the manufacturer's recom-
mendations. All clones were sequenced (Agencourt Bio-
sciences, Beverly, MA) to confirm the nucleotide change
and the remainder of the sequence was inspected to
ensure that no other alterations had occurred during the
site directed mutagenesis process.
Quantitation of the BC+1 alleles
Each of the 10 constructs were co-transfected in triplicate
with pcDNA3.1His/LacZ (Invitrogen Corporation,
Carlsbad, CA) into the WI-38 cell line using LF2000 (Inv-
itrogen Corporation, Carlsbad, CA) according to manu-
facturers recommendations. The pcDNA3.1His/LacZ
vector (Invitrogen Corporation, Carlsbad, CA) was uti-
lized to normalize for transfection efficiency. Five hours
after transfection the media was removed and replaced
with OptiMem (Invitrogen Corporation, Carlsbad, CA).
Forty-eight hours post transfection 200 μl of conditioned
medium was removed from each well and transferred to
1.5 ml eppendorf tubes. The supernatant was clarified by
centrifugation at 12000 × g for 1 minute and 15 μl was
transferred to a luminometer plate. The amount of alka-
A schematic showing the intron-exon structure of ADAM33 and the location of CNSs toward the 5' end of the gene Figure 1
A schematic showing the intron-exon structure of ADAM33 and the location of CNSs toward the 5' end of the 
gene. The results are a comparison of human ADAM33 intron BC and the flanking sequence with the syntenic region of the 
mouse gene. The x axis corresponds to the human reference sequence (GenBank accession no: AF466288) and the y axis cor-
responds to the percent identity for a sliding window of 100 bp. Exons are labeled in blue and show high homology between 
the two species. Intronic regions >75% identical over at least 100 bp are shown in pink where there is a CNS region that is in 
close proximity to SNP BC+1 and two others that reside in intron AB. SNP BC+1 lies within a CNS that is >60% similar to the 
mouse. The promoter is in green showing the direction of transcription.
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line phosphatase protein present in the conditioned
medium was measured using the BD Great EscAPe SEAP
Chemiluminescence (BD Biosciences, Palo Alto, CA) kit
and a Wallace Victor V luminometer following the manu-
facturer's recommendations. Transfection efficiency of the
pcDNA3.1His/LacZ was measured using the Beta Galac-
tosidase Assay Kit (Invitrogen Corporation, Carlsbad, CA)
following the manufacturer's recommendations.
Results
The at-risk allele of BC+1 influences transcription
We hypothesized that a region within intron BC of the
ADAM33 may have the capability to influence the pro-
moter's ability to set the levels of transcription. If so then
based on its location relative to the promoter this regula-
tory region would need to loop back on itself. Thus, the
regulatory region in intron BC would position itself with
the promoter and both would work in concert to produce
the appropriate transcript levels for that cell type [28]. If
this would be the case then the protective (Pr) or at-risk
(Ar) allele may alter the structure of the regulatory region,
which may consequently have an effect on its interaction
with the promoter.
The genetic variant SNP BC+1 (NCBI SNP database acces-
sion number: rs487377) [55] is located at the 5'end of the
ADAM33 gene within intron BC at nucleotide 1212
between exons B and C (Fig. 2A). The polymorphism is an
A to G. The A allele has been shown to be protective and
the G at-risk for asthma [30]. Six overlapping fragments
from intron BC were generated by PCR using BAC RP11-
1098L22 as the template. Four of the six fragments
spanned the polymorphic site and the remaining two
flanked the region. The six fragments were cloned into the
pSEAP 2-control vector upstream of a SV40 promoter and
an alkaline phosphatase reporter gene, which created a
basic model that simulated a simple contextual arrange-
ment of the putative intron BC regulator with a promoter.
The 4 clones that spanned the polymorphic site possessed
the protective (Pr) allele A. Site directed mutagenesis was
employed to replace the A nucleotide and introduce the
at-risk (Ar) allele G into this site (Fig. 2B). The 10 clones
were transformed into the WI-38 cell line and the amount
of alkaline phosphatase protein secreted into the medium
was measured for each construct to quantitate the effects
of the protective and at-risk allele on transcription of the
reporter gene.
The constructs that contained the protective allele A, Con-
struct #1 Pr, #2 Pr, #4 Pr and #6 Pr, produced a measura-
ble amount of alkaline phosphate. These levels were
similar to those produced by the control (+), which con-
tains only the SV40 promoter that drives the transcription
of the alkaline phosphatase reporter gene (Fig. 3). This
result was also observed in the two constructs, Construct
#3 and #5, which flanked the SNP BC+1 region. Con-
versely, the constructs that contained the at-risk allele G,
Results of quantitating the amount of secreted alkaline phos- phatase protein in the medium Figure 3
Results of quantitating the amount of secreted alka-
line phosphatase protein in the medium. The lumines-
cence readings taken from the alkaline phospahatse 
measurements were normalized against the measured 
amount of beta galactosidase to obtain the normalized read-
ings. All constructs that contained the Ar allele showed nor-
malized readings similar to the Basic (-) control, which did 
not possess the SV40 promoter. The opposite result was 
observed for the constructs that contained the Pr allele. Pr 
allele constructs showed normalized readings similar to the 
Control (+), which possessed the SV40 promoter and the 
alkaline phosphatase reporter gene.
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Analysis of SNP BC+1 within intron BC of ADAM33 Figure 2
Analysis of SNP BC+1 within intron BC of ADAM33. 
(A) Schematic showing the location of SNP BC+1 within 
intron BC and the protective (Pr) and at-risk (Ar) alleles A 
and G respectively. (B) Schematic defining the constructs 
generated to analyze the function of the two alleles A and G. 
The PCR generated fragments were cloned into the multiple 
cloning site at the NheI (N) and BglII (B) restriction sites of 
the pSEAP2 Basic vector.
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(Construct #1 At, #2 At, #4 At and #6 At) did not produce
any measurable secreted alkaline phosphatase protein
(Fig. 3). This was similar to the negative control, Basic (-),
which only contains the reporter gene without the SV40
promoter. These results indicated that the genetic variant
at nucleotide position 1212 within intron BC possess a
functional capacity, whose mechanism of action is to
interact with the promoter. Consequently, depending
upon the polymorphism its affect can either have no
influence on transcription, the protective allele A, or it can
abrogate the SV40 promoter, the at-risk allele G, to repress
transcription of the reporter gene and diminish the pro-
duction of the alkaline phosphatase protein.
Analysis of the sequence surrounding the SNP BC+1
To determine whether any regulatory regions reside
within the locale of SNP BC+1 computational tools were
applied to the DNA sequence within intron BC, which
scanned for cis-acting element/s. The sequence surround-
ing the SNP BC+1 was examined for the presence of tran-
scription factor (TF) binding sites using ElDorado
(Genomatix Software GmbH), which graphically displays
all the promoter modules within genes using proprietary
software and public domain information. Fifty one nucle-
otides, 25 nucleotides to the left and to the right of SNP
BC+1, were analyzed for the presence of TFs. When the
protective allele A was present in the sequence, a region
that shared significant similarity to the NFkappaB p50
sub-unit binding site was identified. However, when the
procedure was performed on the same stretch of DNA,
which contained the at-risk allele G a different result was
obtained. The region that shared the homology with
NFkappaB p50 sub-unit was eliminated. NFkappaB is a
ubiquitous transcription factor formed by various homo
and heterodimers of the NFkappaB family and regulates
genes involved in immune and inflammatory responses
[32-34]. These computational studies of the genomic
region surrounding SNP BC+1 indicated that nucleotide
position 1212 within intron BC has the potential to either
introduce or abolish a functional regulatory element.
Discussion
Currently, 42 disease-associated SNPs have been identi-
fied within the asthma-associated ADAM33 gene [30].
While several SNPs have been shown to be associated with
asthma or its sub-phenotypes none have been identified
to possess a functional role that would explain how these
genetic variants could contribute to the disease. This study
demonstrates for the first time that an ADAM33 asthma-
associated SNP, BC+1, does have functional conse-
quences. Through the use of an in vitro model system, we
have demonstrated that the at-risk allele of SNP BC+1 has
an assertive influence on the promoter causing a disrup-
tion to the mechanisms that drive transcription. To under-
stand the implication of this result in the context of
ADAM33 regulation one needs to view these data with
regards to the spatial arrangement of the regulatory region
within the gene. The BC+1 SNP and the surrounding
region were placed upstream of the SV40 promoter in the
in vitro construct, which generated the observed result.
However, this region is located downstream of the
ADAM33 promoter in an intron that is flanked by an
exon. In addition, further upstream of SNP BC+1 there is
intron AB and exon A, which contains the 5'UTR. Thus the
contextual arrangement of the SNP BC+1 region is vastly
different in the ADAM33 gene compared with our in vitro
model system, which possess an intronless reporter gene.
Yet the model system demonstrates that SNP BC+1 lies
within a regulatory region that interacts with the promoter
and is capable of suppressing its role to transcribe the
reporter gene when the at-risk allele G is in the polymor-
phic site. Therefore, it is plausible that this regulatory
region, within intron BC, may work closely with the
ADAM33 promoter and perhaps other as yet undefined
regulatory regions within the gene to influence expression
levels, which are appropriate for a particular cell-type.
Studies have demonstrated that the promoter of a gene
can work in concert with other cis-acting elements, which
couple both transcription and pre-mRNA splicing [35-
37]. In this present study we provide experimental evi-
dence to suggest that the nucleotide position 1212 within
intron BC has a functional role, which is coupled with the
promoter. One allele, the at-risk, appears to generate a
repressor element suppressing expression of the reporter
gene whereas the other, the protective does not cause any
perturbation in protein levels. However, in vivo the mech-
anism of action of the SNP may behave like a rheostat
when combined with other regulatory regions within
ADAM33. As the interactions of these regulatory regions
can be complex, a perturbation that disrupts the modula-
tion of pre-mRNA processing could be subtle yet acutely
felt, in particular in the bronchial smooth muscle cells
and lung fibroblasts, where ADAM33 has been shown to
be expressed [8,38]. Disruptions to the normal modula-
tion of expression levels and splicing patterns that have
been introduced by genetic variants can be a cause or
modifier of human diseases [23]. Consequently, these
subtle effects produced by polymorphic sites such as the
one at BC+1 could be contributors to the pathophysiology
of asthma.
The processing of ADAM33 pre-mRNAs may be influ-
enced by a variety of control elements including the
region around BC+1. This might explain the numerous
alternative splice variants that have been detected [39,40].
In addition ADAMs, which play an important part in the
regulation of cell signaling through cytokine and growth
factor shedding are tightly regulated [41]. ADAM33 is no
exception. Studies have demonstrated that only 10% ofBMC Medical Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2350/8/46
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the ADAM33 protein is localized to the cell surface. The
remainder is packaged into the endoplasmic reticulum
and the proximal Golgi and utilized only under appropri-
ate conditions [42]. The data presented in this paper
would point to the genetic variant within intron BC as one
possible cause for a disruption in the tightly regulated
processing of ADAM33. The ramification of such a pertur-
bation would reverberate through to the protein level
where the isoform ratios could be altered and as such may
augment or diminish the cell signaling mechanisms lead-
ing to a disease outcome [43,44].
Our analysis, using computational tools, of the SNP BC+1
and surrounding DNA sequence has shed some light as to
the type of regulatory element that may reside in intron
BC, and its importance in regulating ADAM33. Compara-
tive studies with the mouse syntenic region has shown
that SNP BC+1 falls within a CNS and is surrounded by
several stretches of conserved nucleotide regions that
extends all the way into intron AB. This has also been
observed in several other vertebrate species [56] and sug-
gests that this region is evolutionarily conserved and has
important functional consequences in the maintenance of
ADAM33. In addition, the SNP BC+1 region shared signif-
icant homology with the NFkappaB p50 sub-unit TF bind-
ing site when the protective allele was present. When the
at-risk allele was inserted the regulatory element was
destroyed. Transcription through the NFkappaB proteins
is usually carried out by DNA binding of up to 5 homo or
hetero dimers of members of this family [45]. Therefore it
is likely that there may be other NFkappaB TF sites in the
CNSs that have yet to be identified and that the one cen-
tered at SNP BC+1 may require these regulatory elements
rather than act on its own. This may also explain that in
our in vitro model system there was a lack of an increase in
transcript expression above the levels of the control (+).
Furthermore, the disruption to NFkappaB regulatory ele-
ments has been shown to be a trigger for the development
of airway diseases [46]. While these computational stud-
ies provide some insight as to the effect of a genetic variant
on a region of DNA, especially within the ADAM33 gene,
further experimental investigation through the use of
Electromobility Shift Assays (EMSA) would need to be
performed to validate the type of proteins that are
recruited to the BC+1 site. We have carried out additional
sequence analysis of the region using Mfold [47], which
predicts the folding of mRNA. These results would suggest
that the change of a single base from A (protective allele)
to G (at-risk allele) at nucleotide1212 within intron BC
can dramatically alter the folding of the mRNA secondary
structure (Fig. 4). These types of affects have been
observed in other studies and demonstrate that a single
base change at a critical point in a gene can have adverse
consequences on mRNA stability, levels of transcription
and alternative splice variants [48-53].
Conclusion
The data presented demonstrate that a disease-associated
SNP within ADAM33, an asthma susceptibility gene, does
have functional consequences. The mechanistic role of
SNP BC+1 appears to be involved in regulating transcrip-
tion levels. While these enlightening data provide an
insight into the role of a disease-associated SNP on the
disruption of ADAM33 regulation it is evident that the
picture is more complex. SNP BC+1 is a common genetic
variant but the at-risk allele appears to have a dramatic
modifying effect in our in vitro model system. However, in
vivo this mode of action is likely to be tempered due to the
complex interplay of regulatory regions in the processing
of the ADAM33 pre-mRNA and may play a role with the
promoter in setting the levels of the alternative spliced
variants. In order to comprehend the complex interplay of
the disease SNPs on ADAM33 gene regulation it will be
necessary to identify other regulatory elements. The loca-
tion of these regions in relationship to disease-associated
SNPs would provide the basis for studying their mecha-
nistic role in pre-mRNA processing. Through the use of
mini-gene model systems [54] it will be possible to glean
a greater understanding of the functional role of these
genetic variants to modulate transcription as well as exon
splicing in ADAM33. These data, combined with under-
standing the functional role of the ADAM33 protein in
airway remodeling (H. Giese and R. Del Mastro, manu-
script in preparation), will lead to unraveling another
piece of the asthma puzzle.
Mfold analysis of the region surrounding the genetic variant  at position 1212 in intron BC of ADAM33 Figure 4
Mfold analysis of the region surrounding the genetic 
variant at position 1212 in intron BC of ADAM33. A) 
The inclusion of the protective allele A; and B) the inclusion 
of the at-risk allele G.
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